Patents by Inventor Katherine Harris

Katherine Harris has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Anti-BCMA heavy chain-only antibodies
    Patent number: 11970540
    Abstract: Anti-BCMA heavy chain-only antibodies (UniAb) and disclosed, along with methods of making such antibodies, compositions, including pharmaceutical compositions, comprising such antibodies, and their use to treat B-cell disorders characterized by the expression of BCMA.
    Type: Grant
    Filed: June 20, 2018
    Date of Patent: April 30, 2024
    Assignee: TENEOBIO, INC.
    Inventors: Nathan Trinklein, Shelley Force Aldred, Katherine Harris, Wim van Schooten
  • ANTI-PSMA ANTIBODIES AND CAR-T STRUCTURES
    Publication number: 20240131074
    Abstract: Anti-PSMA antibodies (e.g., UniAbs™) and CAR-T structures are disclosed, along with methods of making such antibodies and CAR-T structures, compositions, including pharmaceutical compositions, comprising such antibodies and CAR-T structures, and their use to treat disorders that are characterized by the expression of PSMA.
    Type: Application
    Filed: February 25, 2022
    Publication date: April 25, 2024
    Inventors: Starlynn Clarke, Brian Avanzino, Kevin Dang, Nathan Trinklein, Katherine Harris
  • ANTI-BCMA HEAVY CHAIN-ONLY ANTIBODIES
    Publication number: 20240124599
    Abstract: Anti-BCMA heavy chain-only antibodies (UniAb) and disclosed, along with methods of making such antibodies, compositions, including pharmaceutical compositions, comprising such antibodies, and their use to treat B-cell disorders characterized by the expression of BCMA.
    Type: Application
    Filed: September 15, 2023
    Publication date: April 18, 2024
    Inventors: Nathan Trinklein, Shelley Force Aldred, Katherine Harris, Wim van Schooten
  • HEAVY CHAIN ANTIBODIES BINDING TO CD22
    Publication number: 20240117046
    Abstract: Anti-CD22 heavy chain antibodies (e.g., UniAbs™) are disclosed, along with methods of making such antibodies, compositions, including pharmaceutical compositions, comprising such antibodies, and their use to treat B cell disorders that are characterized by the expression of CD22.
    Type: Application
    Filed: December 7, 2023
    Publication date: April 11, 2024
    Inventors: Shelley Force Aldred, Wim van Schooten, Heather Anne N. Ogana, Laura Marie Davison, Katherine Harris, Udaya Rangaswamy, Nathan D. Trinklein
  • ANTI-CD20 ANTIBODIES AND CAR-T STRUCTURES
    Publication number: 20240117063
    Abstract: Ani-CD20 antibodies (e.g., UniAbs™) and CAR-T structures are disclosed, along with methods of making such antibodies and CAR-T structures, compositions, including pharmaceutical compositions, comprising such antibodies and CAR-T structures, and their use to treat disorders that are characterized by the expression of CD20.
    Type: Application
    Filed: September 25, 2023
    Publication date: April 11, 2024
    Inventors: Nathan Trinklein, Katherine Harris, Nicole Allen, Karen Chang, Brian Avanzino
  • Temperature and state of charge based control of dark start auxiliary battery for bidirectional power transfer inverter
    Patent number: 11916429
    Abstract: A power system includes a bidirectional power transfer inverter that receives grid power and can be electrically connected with electric vehicle supply equipment, and an auxiliary battery electrically connected with the bidirectional power transfer inverter and that supplies power to the bidirectional power transfer inverter and electric vehicle supply equipment while the grid power is unavailable.
    Type: Grant
    Filed: December 1, 2021
    Date of Patent: February 27, 2024
    Assignee: Ford Global Technologies, LLC
    Inventors: Timothy Harris, Stuart C. Salter, Ryan O'Gorman, Peter Phung, Katherine Howard-Cone
  • ANTI-CD19 ANTIBODIES AND CAR-T STRUCTURES
    Publication number: 20240042032
    Abstract: Anti-CD19 antibodies (e.g., UniAbs™) and CAR-T structures are disclosed, along with methods of making such antibodies and CAR-T structures, compositions, including pharmaceutical compositions, comprising such antibodies and CAR-T structures, and their use to treat disorders that are characterized by the expression of CD19.
    Type: Application
    Filed: September 22, 2023
    Publication date: February 8, 2024
    Inventors: Nathan Trinklein, Katherine Harris, Brian Avanzino, Joseph S. Lucas, Laura Davison, Blair B. Madison, Karen Chang
  • Agonistic anti-IL-2R antibodies and methods of use
    Patent number: 11884735
    Abstract: Anti-IL2R (e.g., anti-IL2RB, anti-IL2RG, anti-IL2RB/G) antibodies are disclosed, along with methods of making such antibodies, compositions, including pharmaceutical compositions, comprising such antibodies, and use of such antibodies and compositions in the treatment of diseases and disorders that are mediated by the IL2/IL2R signaling pathway.
    Type: Grant
    Filed: February 3, 2023
    Date of Patent: January 30, 2024
    Assignee: TENEOBIO, INC.
    Inventors: Nathan Trinklein, Katherine Harris, Kyle Lorentsen, Harbani Kaur Malik Chaudhry, Kaitlyn Loughlin
  • AGONISTIC ANTI-IL-2R ANTIBODIES AND METHODS OF USE
    Publication number: 20240018250
    Abstract: Anti-IL2R (e.g., anti-IL2RB, anti-IL2RG, anti-IL2RB/G) antibodies are disclosed, along with methods of making such antibodies, compositions, including pharmaceutical compositions, comprising such antibodies, and use of such antibodies and compositions in the treatment of diseases and disorders that are mediated by the IL2/IL2R signaling pathway.
    Type: Application
    Filed: August 29, 2023
    Publication date: January 18, 2024
    Inventors: Nathan Trinklein, Katherine Harris, Kyle Lorentsen, Harbani Kaur Malik Chaudhry, Kaitlyn Loughlin
  • CD3 BINDING ANTIBODIES
    Publication number: 20240018235
    Abstract: The present invention relates to novel human CD3 antigen-binding polypeptides and their preparation and use in the treatment and/or diagnosis of various diseases, and also relates to bispecific antibody molecules capable of activating immune effector cells and their use in diagnosis and/or treatment of various diseases.
    Type: Application
    Filed: January 18, 2023
    Publication date: January 18, 2024
    Inventors: Nathan Trinklein, Wim van Schooten, Shelley Force Aldred, Katherine Harris, Duy Pham
  • Heavy chain antibodies binding to CD22
    Patent number: 11873336
    Abstract: Anti-CD22 heavy chain antibodies (e.g., UniAbs™) are disclosed, along with methods of making such antibodies, compositions, including pharmaceutical compositions, comprising such antibodies, and their use to treat B cell disorders that are characterized by the expression of CD22.
    Type: Grant
    Filed: December 21, 2018
    Date of Patent: January 16, 2024
    Assignee: TENEOBIO, INC.
    Inventors: Shelley Force Aldred, Wim van Schooten, Heather Anne N. Ogana, Laura Marie Davison, Katherine Harris, Udaya Rangaswamy, Nathan D. Trinklein
  • HEAVY CHAIN ANTIBODIES BINDING TO FOLATE RECEPTOR ALPHA
    Publication number: 20240002498
    Abstract: Anti-Folate Receptor Alpha (FOLR1) heavy chain antibodies (e.g., UniAbs™) are disclosed, along with methods of making such antibodies, compositions, including pharmaceutical compositions, comprising such antibodies, and their use to treat disorders that are characterized by the expression of Folate Receptor Alpha (FOLR1).
    Type: Application
    Filed: November 17, 2021
    Publication date: January 4, 2024
    Inventors: Brian Avanzino, Katherine Harris, Hannes Kehm, Nathan Trinklein
  • IMMUNE CELLS HAVING CO-EXPRESSED SHRNAS AND LOGIC GATE SYSTEMS
    Publication number: 20230340139
    Abstract: Provided herein are recombinant nucleic acids encoding chimeric priming receptors that bind ALPG/P, chimeric antigen receptors that bind MSLN, and shRNA that target FAS, PTPN2, and/or TOX. Also provided are systems of chimeric priming receptors that bind ALPG/P, chimeric antigen receptors that bind MSLN, and shRNA that target FAS, PTPN2, and/or TOX, cells expressing such proteins and shRNA, and methods of use thereof.
    Type: Application
    Filed: May 3, 2023
    Publication date: October 26, 2023
    Inventors: Jasper Williams, Michelle Nguyen, Anzhi Yao, Stephen Santoro, Aaron Cooper, John Gagnon, Adam Litterman, Omar Khan, Natalie Bezman, Katherine Harris, Harbani Kaur Malik Chaudhry, Nicole Allen
  • CD3 BINDING ANTIBODIES
    Publication number: 20230272075
    Abstract: The present invention relates to human CD3 antigen-binding polypeptides and their preparation and use in the treatment and/or diagnosis of various diseases, and also relates to bispecific antibody molecules capable of activating immune effector cells and their use in diagnosis and/or treatment of various diseases.
    Type: Application
    Filed: October 3, 2022
    Publication date: August 31, 2023
    Inventors: Nathan Trinklein, Wim van Schooten, Shelley Force Aldred, Katherine Harris, Duy Pham
  • MULTI-SPECIFIC ANTIBODIES BINDING TO BCMA
    Publication number: 20230257473
    Abstract: Multi-specific, human heavy chain antibodies (e.g., UniAbs™) binding to BCMA are disclosed, along with methods of making such antibodies, compositions, including pharmaceutical compositions, comprising such antibodies, and their use to treat disorders that are characterized by the expression of BCMA.
    Type: Application
    Filed: June 30, 2021
    Publication date: August 17, 2023
    Inventors: Nathan Trinklein, Katherine Harris, Harbani Malik, Ute Schellenberger, Omid Vafa, Shelley Force Aldred
  • AGONISTIC ANTI-IL-2R ANTIBODIES AND METHODS OF USE
    Publication number: 20230242653
    Abstract: Anti-IL2R (e.g., anti-IL2RB, anti-IL2RG, anti-IL2RB/G) antibodies are disclosed, along with methods of making such antibodies, compositions, including pharmaceutical compositions, comprising such antibodies, and use of such antibodies and compositions in the treatment of diseases and disorders that are mediated by the IL2/IL2R signaling pathway.
    Type: Application
    Filed: February 3, 2023
    Publication date: August 3, 2023
    Inventors: Nathan Trinklein, Katherine Harris, Kyle Lorentsen, Harbani Kaur Malik Chaudhry, Kaitlyn Loughlin
  • MULTISPECIFIC HEAVY CHAIN ANTIBODIES WITH MODIFIED HEAVY CHAIN CONSTANT REGIONS
    Publication number: 20230203161
    Abstract: Multispecific, human heavy chain antibodies (e.g., UniAbs™) that have modified heavy chain constant regions that impart advantageous properties are provided. The invention further concerns methods of making such antibodies, compositions, including pharmaceutical compositions, comprising such antibodies, and their use to treat disorders that are characterized by expression of one or more of the binding targets described herein.
    Type: Application
    Filed: April 29, 2021
    Publication date: June 29, 2023
    Inventors: Katherine Harris, Ute Schellenberger, Omid Vafa, Nathan Trinklein, Wim Van Schoofen, Shelley Force Aldred, Duy Pham, Starlynn Clarke
  • MESOTHELIN BINDING PROTEINS AND USES THEREOF
    Publication number: 20230192843
    Abstract: Single domain antibodies which specifically bind to mesothelin (MSLN) and mesothelin binding proteins, anti-mesothelin antibodies and antibody fragments thereof, antibody-drug conjugates, synthetic immune receptors, and diagnostic agents comprising the same are disclosed. Also disclosed are pharmaceutical compositions comprising any of the foregoing and uses of any of the foregoing in the treatment and/or diagnosis and/or monitoring of a disease associated with MSLN expression.
    Type: Application
    Filed: October 13, 2022
    Publication date: June 22, 2023
    Inventors: Katherine HARRIS, Harbani Kaur MALIK CHAUDHRY, Nicole ALLEN
  • CD3 binding antibodies
    Patent number: 11613572
    Abstract: The present invention relates to novel human CD3 antigen-binding polypeptides and their preparation and use in the treatment and/or diagnosis of various diseases, and also relates to bispecific antibody molecules capable of activating immune effector cells and their use in diagnosis and/or treatment of various diseases.
    Type: Grant
    Filed: June 20, 2017
    Date of Patent: March 28, 2023
    Assignee: TeneoBio, Inc.
    Inventors: Nathan Trinklein, Wim van Schooten, Shelley Force Aldred, Katherine Harris, Duy Pham
  • CD3 BINDING ANTIBODIES
    Publication number: 20230082151
    Abstract: The present invention relates to human CD3 antigen-binding polypeptides and their preparation and use in the treatment and/or diagnosis of various diseases, and also relates to bispecific antibody molecules capable of activating immune effector cells and their use in diagnosis and/or treatment of various diseases.
    Type: Application
    Filed: August 19, 2022
    Publication date: March 16, 2023
    Inventors: Nathan Trinklein, Wim van Schooten, Shelley Force Aldred, Katherine Harris, Duy Pham